You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-20 of 47 results found

Assays for Measuring and Quantifying DNA Damage

The National Cancer Institute seeks partners interested in licensing or co-development of assays for determining the levels of gamma-H2AX/H2AX to measure and quantify DNA damage.
  • Diagnostics

Human T Cell Receptors for Treating Cancer

T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. The National Cancer Institute's Surgery Branch seeks interested parties to license or co-develop the use of T cell receptors (TCRs) cloned against the SSX-2 antigen for the treatment of cancer.
  • Diagnostics
  • Therapeutics

3D Image Rendering Software for Biological Tissues

The Frederick National Laboratory for Cancer Research seeks parties interested in collaborative research to co-develop software for the automatic 3-D visualization of biological image volumes.
  • Diagnostics
  • Software

Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors

Researchers at the National Cancer Institute (NCI) developed novel groups of cyanine (Cy) based antibody-drug conjugate (ADC) chemical linkers that undergo photolytic cleavage upon irradiation with near-IR light. By using the fluorescent properties of the Cy linker to monitor localization of the ADC, and subsequent near-IR irradiation of cancerous tissue, drug release could be confined to the tumor microenvironment.
  • Diagnostics
  • Therapeutics

Methods of analyzing virus-derived therapeutics

Researchers at the National Cancer Institute’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.
  • Diagnostics

Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy

Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.
  • Diagnostics

A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma

Researchers at the National Cancer Institute (NCI) identified a biomarker signature of viral infection that correlates with hepatocellular carcinoma (HCC) incidence in at-risk individuals. It has been validated in a longitudinal cohort to detect HCC with high sensitivity and specificity up to 7 years prior to clinical diagnosis. This viral exposure signature can be easily implemented into diagnostic assays for screening of HCC and is available for licensing and/or co-development opportunities.
  • Diagnostics

Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens

Researchers at the National Cancer Institute (NCI) have developed a gene-expression profiling-based molecular diagnostic assay to diagnose and classify primary mediastinal large B cell lymphoma (PMBCL) from diffuse large B cell lymphoma (DLBCL). The diagnosis can be done using routinely available formalin-fixed, paraffin-embedded (FFPE) biopsies. The NCI seeks licensees and/or co-development partners to commercialize this technology.
  • Diagnostics

Time Efficient Multi-Pulsed Field Gradient (mPFG) MRI Without Concomitant Gradient Field Artifacts

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research co-development partners and/or licensees for the development of diffusion tensor distribution imaging (DTD-MRI) in assessing disease (e.g., cancer), normal and abnormal developmental processes, degeneration and trauma in the brain and other soft tissues, and other applications.
  • Diagnostics

Synthetic Lethality-mediated Precision Oncology via the Tumor Transcriptome

Scientists at the National Cancer Institute (NCI) have developed SELECT (synthetic lethality and rescue-mediated precision oncology via the transcriptome), a computational precision-oncology framework harnessing genetic interactions to improve treatment options for cancer patients. NCI seeks collaborators or licensees to advance the development of this technology into precision diagnostics.
  • Diagnostics

Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue

Researchers in the National Cancer Institute’s Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. NCI seeks partners to license this technology.
  • Devices
  • Diagnostics
  • Research Tools

Pages